There is a common misconception that patients with stage IV lung cancer receive lower quality of care. While it is true that early stages receive better treatment compared to late stage disease, this article will examine the survival rates for various methods of treatment and co-morbidities that determine the overall prognosis for lung cancer patients.
Given the development and growth of Stage IV cancer requires several years in patients, it is not surprising the patients have to deal with various issues and comorbidities ultimately leading to a poor prognosis.
The 5-year survival rates per treatment option were: * Surgical resection only: **5%** * Stereotactic Body Radiation Therapy + Surgery: **10%** * Immunotherapy alone: **3%**
So, there are no direct links between the treatment options and survival rates. The only things that 5year survival correlates with is a patient's immunity and chance to have side effects from the chemotherapy. It is as if harranguing a lion. Some are scared enough to drop dead soon enough; others are too cocky and try to kill you first. The result plays out similarly in real world practice: **one person with SBR,** or similar local radiation technology, might survive, while three other patients may well die.
On the other end of the spectrum, lung probsing is straightforward and straightforward. Chest xray taken twice in 3 months oatmeal just manages to uncover approximately half of lung nodules already dubbed stage stage 1.